Blue Matter will be sponsoring the BIO-Europe 2026 conference in Cologne, Germany from November 9-11. In addition, Blue Matter Managing Partner, Pankaj Oza, will be moderating a panel discussion at this important meeting:
Build, Buy, or Partner? Choosing Your Market Entry Strategy
For a company at early or later-stage development considering commercialization, few decisions carry more lasting impact than how to enter the market: partnering or licensing with an established regional player, building a commercial organization and launching independently, or some combination of the two. Each path changes the value the company ultimately captures, the capital it must commit, the risk it absorbs, and the organization it becomes.
This panel brings together senior biopharma leaders who chose differing strategic pathways across regions. They will share why each company took the route it did, how the alternatives were weighed against value creation, strategic feasibility, and financial constraints, and how each arrived at the right go-to-market strategy for the region.
Panelists will speak candidly about the lessons they learned, their key success factors, and the things they might have done differently alongside key considerations for companies at an early stage of decisioning.
Time Slot:
Monday, 9 November, 9:00 am CET
Moderator:
Pankaj Oza
Managing Partner, Blue Matter
